应用酒石酸二氢可待因控释片（简称控释片）与酒石酸二氢可待因普通片（简称普通片）随机双盲对照试验，对晚期癌症伴有中、重度疼痛的患者进行镇痛效果及不良反应观察。结果表明：控释片每１２ｈ口服一次可以有效控制晚期癌症慢性中度以上疼痛。与普通片相比较，镇痛效果在日剂量相同的情况下，组间差异无显著性。控释片的不良反应主要有头晕、恶心、呕吐等，与普通片相比，组间差异无显著性 A randomized, double-blind controlled trial of controlled release tablets of dihydrocodeine tartrate (referred to as controlled release tablet) and dihydrocodeine dihydrocodeine tablets (abbreviated as common tablets) was used to analgesic patients with advanced and severe pain accompanied by moderate and severe pain Effect and adverse reaction observed. The results showed that: controlled-release tablets once every 12h oral administration of advanced cancer can effectively control the pain of moderate to moderate chronic. Compared with the ordinary tablets, analgesic effect at the same daily dose, no significant difference between groups. The adverse reactions of controlled release tablets were mainly dizziness, nausea and vomiting, compared with the normal tablets, there was no significant difference between the groups